Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine

Overview

Journal Cancer Genomics Proteomics

Specialties Biochemistry
Genetics
Oncology

Date 2021 May 17

PMID 33994362

Citations 14

Authors

Nurbubu T Moldogazieva

Sergey P Zavadskiy

Alexander A Terentiev

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the sixth most frequently diagnosed cancer and the third leading cause of cancer-related deaths worldwide. Advanced-stage HCC patients have poor survival rates and this requires the discovery of novel clear biomarkers for HCC early diagnosis and prognosis, identifying risk factors, distinguishing HCC from non-HCC liver diseases, and assessment of treatment response. Liquid biopsy has emerged as a novel minimally invasive approach to enable monitoring tumor progression, metastasis, and recurrence. Since the liquid biopsy analysis has relatively high specificity and low sensitivity in cancer early detection, there is a risk of bias. Next-generation sequencing (NGS) technologies provide accurate and comprehensive gene expression and mutational profiling of liquid biopsies including cell-free circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and genomic components of extracellular vesicles (EVs) including micro-RNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). Since HCC is a highly heterogeneous cancer, HCC patients can display various genomic, epigenomic, and transcriptomic patterns and exhibit varying sensitivity to treatment options. Identification of individual variabilities in genomic signatures in liquid biopsy has the potential to greatly enhance precision oncology capabilities. In this review, we highlight and critically discuss the latest progress in characterizing the genomic landscape of liquid biopsy, which can advance HCC personalized medicine.

Citing Articles

Exploring Hepatocellular Carcinoma Pathogenesis: The Influence of Genetic Polymorphisms.

Mollazadeh S, Saeedi N, Al-Asady A, Ghorbani E, Khazaei M, Ryzhikov M Curr Pharm Des. 2024; 31(6):432-442.

PMID: 39297458 DOI: 10.2174/0113816128327773240827062719.

Identification of a lactylation-related gene signature to characterize subtypes of hepatocellular carcinoma using bulk sequencing data.

Chen Y, Chang L, Ling Hu , Yan C, Dai L, Shelat V J Gastrointest Oncol. 2024; 15(4):1636-1646.

PMID: 39279958 PMC: 11399878. DOI: 10.21037/jgo-24-405.

Current updates on the molecular and genetic signals as diagnostic and therapeutic targets for hepatitis B virus-associated hepatic malignancy.

Adugna A, Muche Y, Melkamu A, Jemal M, Belew H, Amare G Heliyon. 2024; 10(14):e34288.

PMID: 39100497 PMC: 11295980. DOI: 10.1016/j.heliyon.2024.e34288.

Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.

Yang J, Lin N, Niu M, Yin B Aging (Albany NY). 2024; 16(14):11460-11474.

PMID: 39033781 PMC: 11315387. DOI: 10.18632/aging.205980.

Extracellular Vesicles as Delivery Vehicles for Non-Coding RNAs: Potential Biomarkers for Chronic Liver Diseases.

Ferro A, Saccu G, Mattivi S, Gaido A, Herrera Sanchez M, Haque S Biomolecules. 2024; 14(3).

PMID: 38540698 PMC: 10967855. DOI: 10.3390/biom14030277.

References

Xue X, Zhao Y, Wang X, Qin L, Hu R . Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. J Cell Biochem. 2018; 120(1):135-142. DOI: 10.1002/jcb.27165. View

Wang G, Liu W, Zou Y, Wang G, Deng Y, Luo J . Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449a-MET pathway. EBioMedicine. 2019; 40:432-445. PMC: 6412851. DOI: 10.1016/j.ebiom.2018.12.062. View

Wang Q, Wang G, Niu L, Zhao S, Li J, Zhang Z . Exosomal MiR-1290 Promotes Angiogenesis of Hepatocellular Carcinoma via Targeting SMEK1. J Oncol. 2021; 2021:6617700. PMC: 7864765. DOI: 10.1155/2021/6617700. View

Takahashi K, Yan I, Wood J, Haga H, Patel T . Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014; 12(10):1377-87. PMC: 4201956. DOI: 10.1158/1541-7786.MCR-13-0636. View

Lin Q, Zhou C, Bai M, Zhu D, Chen J, Wang H . Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis. Am J Transl Res. 2020; 12(3):1080-1095. PMC: 7137059. View

Ng C, Di Costanzo G, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G . Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol. 2018; 29(5):1286-1291. DOI: 10.1093/annonc/mdy083. View

Li Y, Feng W, Kong M, Liu R, Wu A, Shen L . Exosomal circRNAs: A new star in cancer. Life Sci. 2021; 269:119039. DOI: 10.1016/j.lfs.2021.119039. View

Pathan M, Fonseka P, Chitti S, Kang T, Sanwlani R, Van Deun J . Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2018; 47(D1):D516-D519. PMC: 6323905. DOI: 10.1093/nar/gky1029. View

Liu Y, Hu B, Li Z, He X, Li Y, Lu L . An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int. 2016; 10(4):640-6. DOI: 10.1007/s12072-016-9732-7. View

10.

Ou H, Huang Y, Xiang L, Chen Z, Fang Y, Lin Y . Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma. Dig Dis Sci. 2018; 63(9):2373-2380. DOI: 10.1007/s10620-018-5124-2. View

11.

Singal A, Pillai A, Tiro J . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11(4):e1001624. PMC: 3972088. DOI: 10.1371/journal.pmed.1001624. View

12.

Jia F, Wang Y, Fang Z, Dong J, Shi F, Zhang W . Novel Peptide-Based Magnetic Nanoparticle for Mesenchymal Circulating Tumor Cells Detection. Anal Chem. 2021; 93(14):5670-5675. DOI: 10.1021/acs.analchem.1c00577. View

13.

Singh G, Yoshida E, Rathi S, Marquez V, Kim P, Erb S . Biomarkers for hepatocellular cancer. World J Hepatol. 2020; 12(9):558-573. PMC: 7522562. DOI: 10.4254/wjh.v12.i9.558. View

14.

Howell J, Atkinson S, Pinato D, Knapp S, Ward C, Minisini R . Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer. 2019; 116:56-66. DOI: 10.1016/j.ejca.2019.04.014. View

15.

Jiang P, Chan C, Chan K, Cheng S, Wong J, Wong V . Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015; 112(11):E1317-25. PMC: 4372002. DOI: 10.1073/pnas.1500076112. View

16.

Chen Y, Li S, Li W, Yang R, Zhang X, Ye Y . Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci Rep. 2019; 9(1):7084. PMC: 6506548. DOI: 10.1038/s41598-019-43572-1. View

17.

Alix-Panabieres C, Pantel K . Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11(4):858-873. DOI: 10.1158/2159-8290.CD-20-1311. View

18.

Sun Y, Wang P, Cheng J, Gong Z, Huang A, Zhou K . Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathol. 2020; 128(10):733-745. DOI: 10.1002/cncy.22304. View

19.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

20.

Court C, Hou S, Winograd P, Segel N, Li Q, Zhu Y . A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Liver Transpl. 2018; 24(7):946-960. PMC: 6097911. DOI: 10.1002/lt.25062. View